<DOC>
	<DOCNO>NCT00022022</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know chemotherapy regimen effective treat non-small cell lung cancer . PURPOSE : Randomized phase III trial compare two different docetaxel regimen treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare quality life patient stage IIIB IV non-small cell lung cancer treat 2 different schedule docetaxel second-line therapy . - Compare toxicity regimens patient . - Compare response rate , time progression , survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord center , ECOG performance status ( 0 vs 1 v 2 ) , response prior chemotherapy ( partial complete response v stable disease v progressive disease ) , prior cisplatin-containing chemotherapy regimen ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV day 1 . Treatment continue every 3 week maximum 6 course . - Arm II : Patients receive docetaxel IV weekly 6 week . Treatment continue every 8 week maximum 2 course . Quality life assess baseline day 22 43-56 arm I , baseline day 22 43 arm II . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB IV nonsmall cell lung cancer ( NSCLC ) Metastatic supraclavicular lymphadenopathy malignant pleural effusion Progressive disease Must receive prior chemotherapy No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST ALT great 1.25 time ULN Renal : Creatinine great 1.25 time ULN Cardiovascular : No prior concurrent cardiovascular disease would preclude study Pulmonary : See Disease Characteristics No prior concurrent pulmonary disease would preclude study Other : No prior concurrent illness medical condition would preclude study No prior malignancy except adequately treat carcinoma situ cervix nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior docetaxel At least 3 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow No concurrent radiotherapy Surgery : Prior radical surgery NSCLC allow Concurrent palliative surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>